000			01961 a2200505 4500
005			20250513201630.0
264		0	_c20000302
008			200003s 0 0 eng d
022			_a0027-8424
024	7		_a10.1073/pnas.97.2.829 _2doi
040			_aNLM _beng _cNLM
100	1		_aNagy, A
245	0	0	_aStability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. _h[electronic resource]
260			_bProceedings of the National Academy of Sciences of the United States of America _cJan 2000
300			_a829-34 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
650	0	4	_aAdult
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xblood
650	0	4	_aBombesin _xchemistry
650	0	4	_aCarboxylesterase
650	0	4	_aCarboxylic Ester Hydrolases _xantagonists & inhibitors
650	0	4	_aCholinesterase Inhibitors _xpharmacology
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDoxorubicin _xanalogs & derivatives
650	0	4	_aDrug Evaluation, Preclinical
650	0	4	_aDrug Interactions
650	0	4	_aDrug Stability
650	0	4	_aGonadotropin-Releasing Hormone _xanalogs & derivatives
650	0	4	_aHalf-Life
650	0	4	_aHumans
650	0	4	_aHydrolysis
650	0	4	_aIsoflurophate _xpharmacology
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMice, Nude
650	0	4	_aNitrophenols _xpharmacology
650	0	4	_aParaoxon _xpharmacology
650	0	4	_aPyrroles _xpharmacology
650	0	4	_aWeight Loss _xdrug effects
700	1		_aPlonowski, A
700	1		_aSchally, A V
773	0		_tProceedings of the National Academy of Sciences of the United States of America _gvol. 97 _gno. 2 _gp. 829-34
856	4	0	_uhttps://doi.org/10.1073/pnas.97.2.829 _zAvailable from publisher's website
999			_c10594482 _d10594482